CanSino Biologics Inc.

HKSE 6185.HK

CanSino Biologics Inc. Shares (Diluted, Weighted) for the year ending December 31, 2023: 246,766,000

CanSino Biologics Inc. Shares (Diluted, Weighted) is 246,766,000 for the year ending December 31, 2023, a -0.10% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

CanSino Biologics Inc. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 247,022,000, a -0.17% change year over year.
CanSino Biologics Inc. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 247,450,000, a 7.16% change year over year.
CanSino Biologics Inc. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 230,917,000, a 13.50% change year over year.
CanSino Biologics Inc. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 203,455,252, a -6.76% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

HKSE: 6185.HK

CanSino Biologics Inc.

CEO	Dr. Xuefeng Yu Ph.D.
IPO Date	March 28, 2019
Location	China
Headquarters	401-420, Biomedical Park
Employees	1,494
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Key trends

Past 5 years